Why the study?
Is the generic flecainide acetate (Lixarit) bioequivalent to the reference drug (Apocard)?
Is the generic flecainide acetate (Lixarit) bioequivalent to the reference drug (Apocard)?
The article presents bioequivalence data comparing a generic flecainide acetate (Lixarit) to the reference drug (Apocard).
Answers are grounded in this paper and cite their sources.
Supports generic flecainide substitution in arrhythmia care; leaves open outcome equivalence in practice.
The article considers the use of flecainide, an antiarrhythmic agent. The results of comparing the bioequivalence of Lixarit, flecainide acetate generic drug (flecainide acetate, 100 mg tablets, Laboratorios Normon SA, Spain), and Apocard®, flecainide acetate reference drug (Health Care Ltd, UK, 100 mg tablets), are presented.
No takes yet. Share an insight, caveat, or question.
N. Bezditko (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: